AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform
Houston-based AuraVax announces it has entered into an exclusive license option agreement with UH with respect to the intellectual property covering a novel intranasal vaccine technology. Under terms of this agreement, AuraVax has the option to exclusively license patents covering this technology.
Source Name
PR Newswire